The latest price target for Bristol-Myers Squibb (NYSE:BMY) was reported by Truist Securities on January 8, 2025. The analyst firm set a price target for $65.00 expecting BMY to rise to within 12 months (a possible 14.56% upside). 30 analyst firms have reported ratings in the last year.

The latest analyst rating for Bristol-Myers Squibb (NYSE:BMY) was provided by Truist Securities, and Bristol-Myers Squibb maintained their buy rating.

The last upgrade for Bristol-Myers Squibb Co happened on December 16, 2024 when Jefferies raised their price target to $70. Jefferies previously had a hold for Bristol-Myers Squibb Co.

The last downgrade for Bristol-Myers Squibb Co happened on October 25, 2024 when Citigroup changed their price target from $75 to $55 for Bristol-Myers Squibb Co.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bristol-Myers Squibb, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bristol-Myers Squibb was filed on January 8, 2025 so you should expect the next rating to be made available sometime around January 8, 2026.

While ratings are subjective and will change, the latest Bristol-Myers Squibb (BMY) rating was a maintained with a price target of $62.00 to $65.00. The current price Bristol-Myers Squibb (BMY) is trading at is $56.74, which is out of the analyst’s predicted range.